#USA #Denver #EmVenio Clinical Research #PCM Trials #Clinical Trial Service

EmVenio Clinical Research: Setting New Standards in Clinical Trials

On August 25, 2025, a significant transformation was announced in the world of clinical research. PCM Trials, along with its subsidiaries EmVenio Research and Clinical Trial Service, rebranded to EmVenio Clinical Research. This consolidation aims to create a more unified entity that enhances accessibility and flexibility for sponsors and contract research organizations in clinical trials.

The Vision Behind the Rebranding

Greg Austin, president of PCM Trials and now EmVenio Clinical Research, emphasized that merging these three strong companies is pivotal for establishing a new standard in community-based clinical research. By aligning under the EmVenio name, the organization aims to make clinical trials more approachable and accessible. This rebranding communicates a clear mission to increase participation rates across clinical trials, especially in diverse populations, including minorities.

Enhancing Patient Accessibility with New Solutions

As part of its commitment to improving access, EmVenio is unveiling a new service named Patient Navigator™. This initiative is geared towards reducing logistical and financial challenges faced by potential clinical trial participants. Such barriers can be particularly significant in therapeutic areas like rare diseases and pediatric studies. The Patient Navigator service seeks to improve patient retention by providing support tailored to their needs, including travel coordination, accommodation arrangements, and reimbursement assistance. This innovative approach reflects EmVenio's dedication to making clinical trial participation more user-friendly.

A Global Presence for Wider Impact

EmVenio Clinical Research is now operational in over 80 countries, leveraging local research sites and mobile teams that can visit participants within their communities. This global reach allows the organization to engage with populations often overlooked in traditional research models. By bringing clinical studies directly to the patients’ homes or local groups, EmVenio ensures a more diverse and representative sample in clinical trials.

A Legacy of Innovation and Commitment

Founded in 2008, PCM Trials was pivotal in pioneering decentralized clinical trials through specialized mobile nurse visits that conveniently brought trials to participants. Over the years, many innovations introduced by PCM Trials have become industry standards for conducting clinical research.

In 2024, significant acquisitions took place, starting with Clinical Trials Service, followed by EmVenio Research. These strategic moves formed a formidable alliance focused on broadening global access to clinical trials. EmVenio Clinical Research not only boasts decades of experience but also a proven track record of engaging over 75% minority patients in clinical studies and achieving more than 92% retention rates.

The Meaning Behind the Name

The name EmVenio effectively embodies the organization’s mission. It combines the notion of 'empower' with the Latin ‘venio,’ which means 'to reach.' This reflects the firm’s commitment to reaching patients in innovative ways that traditional clinical trial models have failed to achieve.

Looking Ahead

As EmVenio Clinical Research embarks on this new chapter, the focus will shift towards setting new benchmarks for access, flexibility, and precision in clinical trials. The team’s extensive experience and resources position them to provide support that aligns closely with today’s healthcare demands—a progression every research-focused organization should aspire to replicate.

For more information about EmVenio Clinical Research and its offerings, visit emvenio.com. It’s an exciting time in the world of clinical trials, and EmVenio is leading the way towards a more inclusive and accessible research landscape.